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Kirsty Lu, MA; Heidi Murray-Smith, MSc; AndrewWong, PhD; Elizabeth Gordon, MSc; William Coath, MSc; Marc Modat, PhD; David Thomas, PhD;
Marcus Richards, PhD; Nick C. Fox, FMedSci; JonathanM. Schott, MD, FRCP
IMPORTANCE Midlife vascular risk burden is associated with late-life dementia. Less is known
about if and how risk exposure in early adulthood influences late-life brain health.
OBJECTIVE To determine the associations between vascular risk in early adulthood, midlife,
and late life with late-life brain structure and pathology using measures of white
matter–hyperintensity volume, β-amyloid load, and whole-brain and hippocampal volumes.
DESIGN, SETTING, AND PARTICIPANTS This prospective longitudinal cohort study, Insight 46, is
part of the Medical Research Council National Survey of Health and Development, which
commenced in 1946. Participants had vascular risk factors evaluated at ages 36 years (early
adulthood), 53 years (midlife), and 69 years (early late life). Participants were assessed with
multimodal magnetic resonance imaging and florbetapir-amyloid positron emission
tomography scans betweenMay 2015 and January 2018 at University College London.
Participants with at least 1 available imagingmeasure, vascular risk measurements at 1 or
more points, and no dementia were included in analyses.
EXPOSURES Office-based FraminghamHeart study–cardiovascular risk scores (FHS-CVS)
were derived at ages 36, 53, and 69 years using systolic blood pressure, antihypertensive
medication usage, smoking, diabetic status, and bodymass index. Analysis models adjusted
for age at imaging, sex, APOE genotype, socioeconomic position, and, where appropriate,
total intracranial volume.
MAIN OUTCOMES ANDMEASURESWhitematter–hyperintensity volumewas generated from
T1/fluid-attenuated inversion recovery scans using an automated technique and whole-brain
volume and hippocampal volumewere generated from automated in-house pipelines;
β-amyloid status was determined using a gray matter/eroded subcortical white matter
standardized uptake value ratio threshold of 0.61.
RESULTS A total of 502 participants were assessed as part of Insight 46, and 463 participants
(236male [51.0%]) with at least 1 available imagingmeasure (mean [SD] age at imaging, 70.7
[0.7] years; 83 β-amyloid positive [18.2%]) who fulfilled eligibility criteria were included.
Among them, FHS-CVS increased with age (36 years: median [interquartile range], 2.7%
[1.5%-3.6%]; 53 years: 10.9% [6.7%-15.6%]; 69 years: 24.3% [14.9%-34.9%]). At all points,
these scores were associated with smaller whole-brain volumes (36 years: β coefficient per
1% increase, −3.6 [95% CI, −7.0 to −0.3]; 53 years: −0.8 [95% CI, −1.5 to −0.08]; 69 years:
−0.6 [95% CI, −1.1 to −0.2]) and higher white matter–hyperintensity volume (exponentiated
coefficient: 36 years, 1.09 [95% CI, 1.01-1.18]; 53 years, 1.02 [95% CI, 1.00-1.04]; 69 years, 1.01
[95% CI, 1.00-1.02]), with largest effect sizes at age 36 years. At no point were FHS-CVS
results associated with β-amyloid status.
CONCLUSIONS AND RELEVANCE Higher vascular risk is associated with smaller whole-brain
volume and greater white matter–hyperintensity volume at age 69 to 71 years, with the
strongest association seen with early adulthood vascular risk. There was no evidence that
higher vascular risk influences amyloid deposition, at least up to age 71 years. Reducing
vascular risk with appropriate interventions should be considered from early adulthood to
maximize late-life brain health.
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Published online November 4, 2019.
Editorial
Supplemental content
Author Affiliations:Author
affiliations are listed at the end of this
article.
Corresponding Author: JonathanM.
Schott, MD, FRCP, Dementia
Research Centre, UCL Queen Square
Institute of Neurology, PO Box 16,
Queen Square, LondonWC1N 3BG,
United Kingdom (j.schott@ucl.ac.uk).
Research
JAMANeurology | Original Investigation
(Reprinted) E1
Downloaded From: https://jamanetwork.com/ by a London Sch of Hygiene & Tropical Medicine User  on 11/11/2019
D ementia affects 44million peopleworldwide, a num-ber expected to triple by 2050.1 Vascular risk factors,including hypertension,2 obesity,3 diabetes,4 and
smoking,5 are implicated in the development of late-life cog-
nitive impairment. Midlife (considered to span ages 40 years
to65years) rather than late-life risk exposure is generally con-
sideredmore critical.6 However, there has been little investi-
gation into the influence of vascular risk prior tomidlife. Ap-
propriate timing of vascular screening programs and
interventions will be necessary to maximize benefits to cog-
nitive health at both an individual and population level.
Vascular risk burden confers increased risk for clinically
diagnosedvascular dementia andalsoAlzheimerdisease (AD)
dementia (albeit to a lesser extent).7 The pathologicalmecha-
nisms by which vascular risk factors mediate cognitive de-
cline are not well understood, with conflicting evidence over
whether vascular risk burden directly enhances β-amyloid
deposition,8,9 a cardinal feature of AD, in addition to its well-
established role in cerebral small-vessel disease. TheAPOE ε4
allele, the most important genetic risk factor for develop-
ment of sporadic AD, is thought to influence β-amyloid dep-
ositionvia alterations in its clearance.10WhetherAPOE ε4also
modulates the association of vascular risk factors with cere-
bral pathology, as has beenpreviously suggested,11 remains to
be clarified.
Individuals from the Medical Research Council National
Survey of Health and Development (NSHD; the British 1946
birth cohort) have had vascular phenotyping since their 30s,
and now a subset have had multimodal magnetic resonance
imaging and β-amyloid imaging. This allowed us to investi-
gate the influence of vascular risk exposure timing on brain
structure and pathology at age 69 to 71 years, with a specific
focus on cerebral small-vessel disease, β-amyloid deposition,
and brain volumes, using measures from early adulthood,
midlife, and early late life. We hypothesized that (1) the
strongest association between vascular risk burden and late-
life brain structure and pathology would be observed with
midlife risk exposureand (2) the influenceofvascular riskbur-
den on brain structure and pathology would be modified by
APOE ε4 allele status.
Methods
Study Design and Participants
Study participants were from Insight 46, a substudy of the
NSHD that initially included 5362 individuals born through-
outmainland Britain in a singleweek in 1946.12 Eligibility cri-
teria for Insight 4613 (eMethods in the Supplement for more
detail) and comparisons with the larger NSHD14 have previ-
ouslybeen reported.A total of 502participants attendeddata-
collection sessions atUniversityCollegeLondonbetweenMay
2015 and January 2018,where they underwent detailed clini-
cal, cognitive, and brain-imaging assessments.13
Ethical approvals for the wider NSHD study have been
described.15 This studywas approvedby theQueenSquare re-
search ethics committee; all participants providedwritten in-
formed consent.
Procedures
Imaging was performed on a single Biograph mMR 3T posi-
tronemission tomography (PET)/magnetic resonance imaging
(MRI) scanner (Siemens Healthcare), with simultaneous ac-
quisition of dynamic PET/MRI data, including volumetric
(1.1-mm isotropic) T1 and fluid-attenuated inversion recov-
ery (FLAIR) sequences, at age 69 to 71 years.13 The β-amyloid
burden was assessed using 18F-florbetapir (Amyvid). Posi-
tron emission tomography datawas processed using an auto-
mated in-house processing pipeline including pseudo–
computed tomography attenuation correction.13 The global
standardized uptake value ratio was calculated from cortical
regionsof interest (including the lateral andmedial frontal, an-
terior, andposterior cingulate; lateral parietal; and lateral tem-
poral regions), normalized to eroded subcortical white mat-
ter.Positiveornegativeβ-amyloidstatuswasdeterminedusing
a Gaussian mixture model applied to standardized uptake
value ratio values, taking the 99th percentile of the lower
(β-amyloid negative) Gaussian plot as the cut point (0.61).
The T1-weighted and FLAIR images underwent visual
quality control, before processing using the following auto-
mated pipelines13: whole-brain volume (WBV) segmentation
using Multi-Atlas Propagation and Segmentation,16 hippo-
campal volume (HV) using Similarity and Truth Estimation
for Propagated Segmentations17 (both with manual editing
if required), and total intracranial volume using SPM12
(Wellcome Centre for Human Neuroimaging).18 A validated,
unsupervised automated algorithm, Bayesian model selec-
tion (BaMoS)19 was used to segment white matter hyperin-
tensities (WMH) from T1/FLAIR images, followed by visual
quality control and editing if required, generating a global
WMH volume (WMHV) including subcortical gray matter
but excluding infratentorial regions.
Vascular Risk Factors and Other Co-Variates
Vascular risk factors have been measured at in-person visits
sinceage36years (except serumcholesterol levels,whichwere
only collectedat ages 53years and69years). Therefore, for the
purposes of this analysis, office-based Framingham Heart
Study–cardiovascular risk scores (FHS-CVS),which donot re-
quire serum cholesterol levels for calculation, were derived
Key Points
Question When is vascular risk during adulthood (early
adulthood, midlife, or late life) most strongly associated with
late-life brain structure and pathology?
Findings In a propective cohort of 463 participants free of
dementia from the population-based Insight 46 study, higher
vascular risk in early adulthood wasmost strongly associated with
smaller whole-brain volumes and greater white matter–
hyperintensity volumes at age 69 to 71 years. There were no
associations at any age with amyloid status.
Meaning These findings are consistent with vascular risk
influencing late-life brain health via cerebral small-vessel disease
and lower brain volumes but not amyloidosis; vascular risk
screening andmodificationmay need to be considered from early
adulthood.
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from measurements collected on home visits by research
nurses when participants were age 36 years (early adult-
hood), 53 years (midlife), and69years (early late life), prior to
their Insight 46 visit. The FHS-CVS provides a 10-year risk of
cardiovascular events. It ismadeupof aweighted sumof age,
sex, systolic bloodpressure, antihypertensivemedicationus-
age (yes/no),historyofdiabetes (yes/no), current smoking (yes/
no), and body mass index (BMI; calculated as weight in kilo-
grams divided by height in meters squared).20 Seated blood
pressure was measured in the upper arm twice after 5 min-
utes of rest. At age 36years, aRandomZero sphygmomanom-
eter (Hawksley) was used; at ages 53 years and 69 years, an
HEM-705 automated digital oscillometric sphygmomanom-
eter (Omron) was used. To ensure compatibility, published
conversion equations were applied.21 The second systolic
blood pressure measure was used for analyses, unless data
were missing. Prescription medication usage was self-
reported: at each point, individuals were categorized accord-
ing to antihypertensive medication usage.22 Smoking status
was defined by questionnaire: for participants aged 69 years,
this was collected from a postal questionnaire they had com-
pleted at age 68 years, and if these data were missing, we col-
lected this from questionnaires completed at age 60 to 64
years. Diabetes mellitus status was based on self-reported
diagnosis at age 36 years, and at ages 53 and 69 years, it was
based on self-reported diagnosis or a hemoglobin A1C level of
6.5% or more (to convert to a proportion of total hemoglobin,
multiply by 0.01).
For descriptive purposes, hypertension was defined as
either a blood pressure of 140 over 90 mm Hg or a self-
reported clinical diagnosis at each point. Obesitywas defined
as a BMI of 30 or more. Hypercholesterolemia status was de-
fined as random serum cholesterol level of 193.4 mg/dL (5
mmol/L or more; to convert to mmol/L, multiply by 0.0259)
and/or, at age 69 years, self-reported use of a cholesterol-
lowering medication.
We performed APOE genotyping using standard tech-
niques from samples available at age 53 years,23 or if miss-
ing, at age 69 to 71 years, and individuals were categorized
as having or not having at least 1 APOE ε4 allele. Adult
socioeconomic position was defined as nonmanual labor or
manual labor, based on occupation at age 53 years, accord-
ing to the United Kingdom Registrar General’s Classification
of Occupations.
Statistical Analysis
Analyseswere performed in Stata version 14.1 (StataCorp). To
be included,participantsneeded tobe freeofdementiaper ex-
pert consensus informed by clinical history, informant his-
tory,andMini-MentalStateExamination(score≥26)24andhave
acceptable-qualityamyloidpositronemission tomographyand
magnetic resonance imaging,knownAPOEε4status, andcom-
plete vascular risk factors information at 1 ormore points. For
WMHV and brain-volume analyses, individuals with cortical
infarcts inappropriately segmented (n = 5) orwhitematter pa-
thologies not considered vascular in origin (eg, demyelin-
ation; n = 3), were excluded. For brain-volume analysis, indi-
viduals also required a useable amyloid scan.
Separate analyses were performed to investigate associa-
tions between FHS-CVS at each age and each imaging mea-
sure. Because of the nonnormal distribution of WMHV, gen-
eralized linear models using the gamma distribution and log
link were used to investigate associations withWMHV. Logis-
tic regression models were used to investigate associations
with β-amyloid status, and linear regression was used to
investigate associations with WBV and mean HV. Models
were adjusted for sex, scanning age, adult socioeconomic
position, APOE ε4 status and (for WMHV and brain-volume
models) total intracranial volume. Differential influences of
FHS-CVS on imaging outcomes by APOE ε4 status and sex
were tested by introduction of appropriate interaction terms
into models. We did not correct for multiple comparisons
because we were interested in examining the association at
each time point separately. For each imaging outcome, effect-
size differences between points were investigated by includ-
ing FHS-CVS at the 3 ages in a joint model and testing for an
age interaction, accounting for clustering using robust stan-
dard errors.
Generalized linear models and linear regression model
assumptionswereconfirmedbyexaminationof residualsplot-
ted against fitted values. Logistic regression model assump-
tions were also assessedwith the Hosmer-Lemeshow test for
goodness of fit. Model checking indicated no material viola-
tion of assumptions or highly influential data points. Statisti-
cal significance was set at P < .05.
In a sensitivity analysis,multiple imputationwasused for
the66 individuals excludedbecauseofmissing covariate data
(eMethods in the Supplement). A further exploratory analy-
sis sought to investigatewhether a higher number of vascular
risk factors, rather than aweighted risk score, was associated
with imagingmeasures.Becauseof thepreviously reportedas-
sociationbetweenmoremidlifevascular risk factors (usingcur-
rent smoking, hypertension, diabetes, obesity, and elevated
totalcholesterol)and late-lifeβ-amyloiddeposition,8wesought
to replicate this finding and extend it to other imaging mea-
sures by categorizing the number of risk factors as 0, 1, or 2 or
more. This analysiswas onlyperformedonparticipants at age
53 years and 69 years, since serum cholesterol was unavail-
able for participants at age 36 years.
Results
Of 502 individuals assessed, 471 (93.4%) completed the
imaging protocol; of these, 468 (93.2%) were free of demen-
tia. A total of 463 participants (236 male participants
[51.0%]; mean [SD] age at imaging, 70.7 [0.7] years) were
included in the sample.
Following imaging processing and quality control, 455
individuals (90.6%) were available for amyloid analysis, 443
individuals (88.2%) forbrain-volumeanalysis, and451 (89.8%)
for WMHV analysis; all of these participants had necessary
covariate data. (eFigure 1 in the Supplement summarizes re-
cruitmentandavailabledata.)Ageat imagingwassimilaracross
individuals. Participant characteristics are summarized in
Table 1, including numberswith available vascular profiles at
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each age. (eTables 1-3 in the Supplement show comparisons
of characteristics between those with and without missing
data.) Participants in Insight 46 had marginally lower
FHS-CVS results than in the full NSHD cohort (median [inter-
quartile range (IQR)]: age 36 years, 2.7% [1.5%-3.6%] vs 2.9%
[1.7%-4.3%]; age 53 years, 10.9% [6.7%-15.6%] vs 12.2%
[7.6%-18.8%]; age 69 years, 24.3% [14.9%-34.9%] vs 25.0%
[15.3%-36.5%]; eTable 4 in the Supplement).
Associations Between Vascular Risk Scores and Global
WMHV at Age 69 to 71 Years
Highervascular riskscoreswereassociatedwithhigherWMHV.
The effect size increased the earlier the FHS-CVS was mea-
sured (exponentiated coefficients: age 36 years, 1.09 [95%CI,
1.01-1.18];P = .04;age53years, 1.02[95%CI, 1.00-1.04];P = .03;
age 69 years, 1.01 [95%CI, 1.00-1.02; P = .02; Table 2; Figure;
eFigure 2 in the Supplement). There was a significant differ-
ence in the effect size by age of risk measurement (interac-
tion P < .001). There was no evidence of a sex or APOE ε4
interaction.
Associations Between Vascular Risk Scores and β-Amyloid
Status at Age 69 to 71 Years
There was no association between vascular risk scores at any
time point (ages 36, 53, or 69 years) and β-amyloid status at
age 69 to 71 years (Table 2; Figure). Effect sizes did not differ
betweenagesofvascular riskmeasurements.Therewasnoevi-
dence of sex or APOE ε4 interactions.
Table 1. Participant Characteristics Including Vascular Risk Profiles at Ages 36 Years, 53 Years,
and 69 Years and Imaging OutcomeMeasures
Characteristic
No. (%)
Age at Home Visit, y
Insight 46 Imaging
Assessment36 53 69
Total, No. 418 449 450 463
Age, mean (SD), y 36.3 (0.2) 53.4 (0.2) 69.5 (0.2) 70.7 (0.7)
Male 213 (51.0) 229 (51.0) 232 (51.6) 236 (51.0)
Adult socioeconomic position
Nonmanual labor 360 (86.1) 383 (85.3) 386 (85.8) 393 (84.9)
Manual labor 58 (13.9) 66 (14.7) 64 (14.2) 70 (15.1)
APOE ε4 carrier statusa 128 (30.6) 129 (28.7) 130 (28.9) 137 (29.6)
Systolic blood pressure, mean (SD), mm Hg 120.3 (13.8) 133.6 (19.2) 132.4 (16.0) NA
Use of antihypertensive medication 7 (1.8) 53 (11.8) 180 (40.0) NA
Hypertension 66 (15.8) 207 (46.1) 253 (56.4) NA
BMI, mean (SD) 23.7 (3.1) 26.9 (4.0) 27.6 (4.4) NA
Obesity 13 (3.1) 77 (17.2) 117 (26.0) NA
Current smoker 82 (19.6) 41 (9.1) 16 (3.6) NA
Diabetes 1 (0.2) 13 (2.9) 47 (10.4) NA
Hypercholesterolemia NR 348 (86.4) 364 (80.0) NA
Office-based FHS-CVS, median (IQR), %b 2.7 (1.5-3.6) 10.9
(6.7-15.6)
24.3
(14.9-34.9)
NA
No. of participants with vascular risk
factors recordedc
NR 403 455 NA
No. of vascular risk factorsc
0 NR 27 (6.7) 42 (9.2) NA
1 NR 165 (40.9) 141 (31.0) NA
2 NR 147 (36.5) 174 (38.2) NA
3 NR 60 (14.9) 82 (18.0) NA
4 NR 4 (1.0) 16 (3.5) NA
5 NR 0 0 NA
Amyloid-positive. No./total No. of
participants (%)
NR NR NR 83/455 (18.2)
Global white matter hyperintensity volume,
median (IQR), mL
NR NR NR 3.1 (1.6-6.8)
Total No. of participants NR NR NR 451
Whole-brain volume, mean (SD), mL NR NR NR 1100 (98)
Total No. of participants NR NR NR 443
Mean hippocampal volume, mean (SD), mL NR NR NR 3.1 (0.3)
Total No. of participants NR NR NR 443
Total intracranial volume, mean (SD), mL NR NR NR 1434 (132)
Total No. of participants NR NR NR 451
Abbreviations: BMI, bodymass index
(calculated as weight in kilograms
divided by height in meters squared);
FHS-CVS, FraminghamHeart
Study–cardiovascular risk score; IQR,
interquartile range; NA, not
applicable; NR, not recorded.
a Presence of 1 or 2 alleles.
b The office-based FHS-CVS provides
a 10-year risk of cardiovascular
events (as a percentage). It is made
up of a weighted sum of age, sex,
systolic blood pressure, use of
antihypertensive medication
(yes/no), history of diabetes
(yes/no), current smoking (yes/no),
and BMI.
c For the purposes of exploratory
analyses, vascular risk factors
included current smoker status,
presence of obesity, presence of
diabetes, raised total cholesterol,
and presence of hypertension.
Information on cholesterol was not
available at age 36 years.
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Associations Between Vascular Risk Scores and Brain
Volumes at Age 69 to 71 Years
Higher vascular risk scoreswere associatedwith smallerWBV,
and theeffect size increased theearlier theFHS-CVSwasmea-
sured (β coefficient: age 36 years, –3.6 [95% CI, –7.0 to –0.3];
P = .03; age 53 years, –0.8 [95%CI, –1.5 to –0.08]; P = .03; age
69years, –0.6 [95%CI, –1.1 to –0.2];P = .003; Table 2; Figure).
AhigherFHS-CVSat age36yearswasassociatedwitha smaller
mean HV (β coefficient: age 36 years, –0.03 [95% CI, –0.05 to
–0.004]; P = .02; Table 2; Figure). When WBV was included
in thismodel, the associationwas no longer significant (β co-
efficient, −0.018 [95%CI, −0.038 to0.003];P = .09). Associa-
tionswithWBVremainedstatistically significantwhenβ-amy-
loid status and WMHV were introduced into models (β
coefficient: age 36years, –3.7 [95%CI, –7.1 to –0.3];P = .03; age
53years, –0.8 [95%CI, –1.5 to –0.07];P = .03; age69years, –0.6
[95% CI, –1.1 to –0.2]; P = .003; eTable 5 in the Supplement).
There was a significant difference in the effect size of
vascular risk burden by age of risk measurement on WBV (β
coefficients from interactionmodel: age 36 years, –3.7; age 53
years, –1.0; and age69years, –0.5; interactionP = .02) but not
mean HV.
We initially observed a significant interaction between
sex and FHS-CVS on WBV assessment at age 36 years only
whereby higher vascular risk scores were associated with
smaller WBV, but this only reached significance in women (β
coefficient, −11.2 [95% CI, –19.3 to –3.0]; P = .008 in women;
β coefficient, −2.1 [95% CI, −5.8 to 1.6]; P = .27 in men; inter-
action P = .048). There were no significant sex interactions
observed at other ages or when examining mean HV. There
Figure. Plots Showing the Effect Sizes of a 1% Increase in FraminghamHeart Study–Cardiovascular Risk Score
at Ages 36, 53, and 69 Years on Imaging OutcomeMeasures at Age 69 to 71 Years
0.90 1.201.10
WMHV Exponentiated Coefficient
1.00
P Value
Smaller
Volume
Larger
VolumeAge, y
Exponentiated
Coefficient (95% CI)
.0436 1.09 (1.01 to 1.18)
.0353 1.02 (1.00 to 1.04)
.01569 1.01 (1.00 to 1.02)
White matter hyperintensity volumeA
Adjusted Odds Ratio
for β-Amyloid Positivity
P Value
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Amyloid
Negativity
Favors
Amyloid
PositivityAge, y
Adjusted Odds Ratio 
(95% CI)
.8536 0.98 (0.79 to 1.21)
.1953 0.97 (0.92 to 1.02)
.5069 0.99 (0.97 to 1.02)
β-Amyloid positivityB
–8 2–2
WBV β Coefficient
–6 0–4
P Value
Smaller
Volume
Larger
VolumeAge, y
β Coefficient
(95% CI)
.0336 –3.64 (–7.00 to –0.30)
.0353 –0.78 (–1.50 to –0.08)
.00369 –0.64 (–1.10 to –0.20)
Whole-brain volumeC
–0.06 0.020
Mean HV β Coefficient
–0.04 –0.02
P Value
Smaller
Volume
Larger
VolumeAge, y
β Coefficient
(95% CI)
.02136 –0.0300 (–0.01 to 0.004)
.9653 –0.0001 (–0.01 to 0.004)
.9669 –0.0001 (–0.00 to 0.003)
Hippocampal volumeD
10.80 0.90 0.10 0.20
HV indicates hippocampal volume; WBV, whole-brain volume; WMHV, white matter–hyperintensity volume.
Table 2. Associations Between FraminghamHeart Study–Cardiovascular Risk Scores at Ages 36, 53, and 69 Years andWhiteMatter
Hyperintensity Volume, Amyloid Status,Whole-Brain Volume, andMeanHippocampal Volume at Age 69 to 71 Yearsa
Age,
y
White Matter–Hyperintensity
Volume, mL Amyloid Status Whole-Brain Volume, mL
Mean Hippocampal
Volume, ml
Participants,
No.
Exponentiated
Coefficient
(95% CI)
P
Value
Participants,
No.
Adjusted
Odds Ratio
(95% CI)
P
Value
Participants,
No.
β Coefficient
(95% CI)
P
Value
Participants,
No.
β
Coefficient
(95% CI)
P
Value
36 407 1.09
(1.01-1.18)
.04 410 0.98
(0.79-1.21)
.85 399 –3.6
(–7.0 to –0.3)
.03 399 –0.03
(–0.05 to
–0.004)
.02
53 438 1.02
(1.00-1.04)
.03 441 0.97
(0.92-1.02)
.19 430 –0.8
(–1.5 to –0.08)
.03 430 –0.0001
(–0.005 to
0.004)
.96
69 438 1.01
(1.00-1.02)
.02 442 0.99
(0.97-1.02)
.50 430 –0.6
(–1.1 to –0.2)
.003 430 0.0001
(–0.003 to
0.003)
.96
a Coefficients represent the change in imaging outcomesmeasures per 1%
increase in FraminghamHeart Study–cardiovascular risk scores. For instance, a
1% increase in score at age 36 years is associated with 9% higher white
matter–hyperintensity volume, 3.6-mL smaller whole-brain volume, and a
0.03-mL smaller mean hippocampal volume. All models are adjusted for sex,
age at time of scanning, APOE ε4 status, adult socioeconomic position, and
(where appropriate) total intracranial volume.
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were no significant interactions with APOE-ε4 status except
at age 69 years, at which point an interaction between APOE
ε4 status and FHS-CVS was initially observed on the ex-
pected mean HV, whereby in individuals carrying at least 1
APOEε4allele, an increasingvascular risk scoreat age69years
was associatedwith a largermeanHV,while in thosewithout
this allele, an increasing score was associated with a smaller
mean HV. However, in neither group was the association sig-
nificant (thosewith at least 1 allele: β coefficient, 0.0028 [95%
CI, −0.001 to0.0067];P = .15; thosewithout at least 1 allele: β
coefficient, −0.0015 [95%CI, −0.0046 to 0.0016]; P = .35; in-
teraction P = .045).
Associations Between Covariates and BrainMeasures
Associations are summarized in eTable 6 in the Supplement.
The individualswith at least 1APOE ε4 alleleweremore likely
to have β-amyloid positivity (odds ratio, 5.16 [95% CI, 3.02-
8.81];P < .001), but thiswasnot associatedwithother imaging
outcomes.
Associations Between ImagingMeasures
and a Cumulative Vascular Risk Score
Increasingnumbersofvascular risk factorsat age53or69years
were not associated withWMHV or brain volumes. The pres-
ence of 2 or more vascular risk factors at age 69 years was as-
sociated with a decreased likelihood of β-amyloid positivity
(odds ratio, 0.40 [95% CI 0.18-0.91]; P = .03; Table 3).
Sensitivity Analysis
Imputingmissing FHS-CVSdata (for 463 participants) did not
significantly alter findings. Details are presented in eTable 7
in the Supplement.
Discussion
In this study of individuals who were free of dementia, all of
whom were nearly identical in age at the times of assess-
ments, we demonstrate that the association of vascular risk
withWMHVandbrain volumes at age 69 to 71 years increases
the earlier vascular risk is present, with the strongest influ-
ence at age 36 years. Therewas no evidence of an association
between vascular risk and β-amyloid status when using the
FHS-CVS score. These findings support the concept that vas-
cular risk is associated with subsequent cognitive health
throughvascularpathwaysand influencesonbrainvolumebut
not β-amyloid deposition at age 69 to 71 years. Furthermore,
findings support that while midlife is an important period of
risk exposure, influences of vascular risk on brain structure
extend back into early adulthood and may be particularly
damaging at this time or may alternatively reflect increased
accumulated risk exposure.
Associationsbetweenvascular risk factors, cerebral small-
vessel disease, smaller brain volumes, and cognitive impair-
ment are widely reported.25 Although it is generally consid-
ered that midlife, rather than late-life risk exposure is more
critical, direct comparisons between points are rarely re-
ported. A recent study by the Framingham cohort used an
associated composite vascular risk score (the Framingham
StrokeRiskProfile) anddemonstratedstrongerassociationsbe-
tween vascular risk burden at younger ages (as young as 45
years) and late-life brain volumes.26 We extend these find-
ings by demonstrating that this temporal association exists
with bothWBV andWMHV, a proxymarker of cerebral small-
vessel disease. Furthermore, the strongest associations were
Table 3. Associations Between Increasing Numbers of Vascular Risk Factors at Ages 53 and 69 Years
and Cerebral OutcomeMeasures at Age 69 to 71 Yearsa
Factor
White Matter Hyperintensity
Volume, mL Amyloid Status
Whole-Brain
Volume, mL
Mean Hippocampal
Volume, mL
Exponentiated
Coefficient
(95% CI) P Value
Adjusted Odds Ratio
(95% CI) P Value
β Coefficient
(95% CI) P Value
β Coefficient
(95% CI) P Value
Participants with
vascular risk factor
status at age 53 y,
No.
393 NA 395 NA 385 NA 385 NA
Vascular risk factors
None [Reference] NA [Reference] NA [Reference] NA [Reference] NA
1 1.12 (0.71-1.74) .63 1.21 (0.37-3.91) .76 –8.9 (–27.3 to 9.5) .34 –0.02 (–0.14 to 0.11) .78
≥2 1.40 (0.91-2.17) .13 0.85 (0.26-2.75) .79 –14.2 (–32.3 to 4.0) .13 –0.04 (–0.17 to 0.08) .47
Participants with
vascular risk factor
status at age 69 y,
No.
443 NA 447 NA 435 NA 435 NA
Vascular risk factors
None [Reference] NA [Reference] NA [Reference] NA [Reference] NA
1 0.94 (0.64-1.39) .75 0.46 (0.19-1.11) .08 6.2 (–9.9 to 22.2) .45 0.09 (–0.02 to 0.19) .10
≥2 1.20 (0.83-1.74) .33 0.40 (0.18-0.91) .03 –6.4 (–21.4 to 8.6) .40 0.08 (–0.01 to 0.18) .09
Abbreviation: NA, not applicable.
a Models are adjusted for sex, adult socioeconomic position, APOE ε4 status, age at scanning, and (where appropriate) total intracranial volume.
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observedusingmeasuresatage36years,which isyounger than
previously reported. This is consistent with the recent obser-
vation of cross-sectional associations between cerebrovascu-
lar imaging markers and cardiovascular risk factors in young
adults.27 Importantly, even at the low risk levels seen at this
age, a 1% increase in risk can have a substantial influence 3
decades later. It should be noted that a 1% absolute increase
in risk at age 36 years is amuch larger relative increase in vas-
cular risk thanat later agesbecauseof relatively lowrisk scores
at that point. From a practical perspective however, even
though a 10-year cardiovascular risk less than 10% is consid-
ered to be low risk, this study supports that changes in this
range are still damaging to subsequent cerebral health.
Wenoteda stronger associationbetweenvascular risk and
late-life brain volume in women at age 36 years only. A simi-
lar association in younger women only was reported by Pase
et al,26 who suggested it may reflect individuals who are par-
ticularlyunhealthy for their age, sincehighvascular risk is un-
usual inwomenwhoare premenopausal.However, in this co-
hort, the range of FHS-CVS risk scores in women were lower
than those of men, with a similar spread around normal age-
adjusted risk.20Aheightenedvulnerability inwomenwhoare
premenopausalmightbeassociatedwithsexdifferences invas-
cular remodeling causing microvascular disease, which has
been demonstrated in coronary artery disease.28 We did not
observeasimilar interactionwhenexaminingassociationswith
WMHV. Since microvascular sequelae also include microin-
farcts that influence atrophy,29 this association might be ob-
served independently of conventional cerebral small-vessel
disease imaging markers. Indeed, associations between vas-
cular risk andWBV persisted withWMHV adjustment. Alter-
natively, the larger effect size in women might be associated
with theunderestimationof truecardiovascular risk inwomen
when scores such as the FHS-CVS are used.30
Wedidnot findapositiveassociationbetweenvascular risk
scores andbrain amyloidosis in late life. Previous findings are
inconsistent: 1 study31 found a cross-sectional positive asso-
ciationbetween theFraminghamcoronary risk scoreandbrain
β-amyloid in older individuals, while a recent Atherosclero-
sis Risk in Communities study found an association with in-
creasingnumber of vascular risk factors inmidlife but not late
life.8 Using a similar measure, we did not find an association
with midlife vascular risk factors, which might be accounted
forbycohortdifferences, including theyounger ageat imaging
in Insight 46 (in the Atherosclerosis Risk in Communities
study, the mean age was 76 years). Using a cumulative count
of vascular risk factors inmidlife and late life to investigate as-
sociationswithbrainvolumesandWMHVdidnot replicate the
findings using the FHS-CVS score, demonstrating the impor-
tanceofusing avalidated, appropriatelyweighted scorewhen
assessing overall vascular risk.
In late life, however,weobserved that a higher number of
vascular risk factors was associated with decreased likeli-
hoodofβ-amyloid-positivity. Thismay reflect a selectionbias,
since those who have a higher vascular burden and are also
β-amyloid-positive may be more likely to be cognitively im-
paired and refuseparticipation.Alternatively, sinceBMI32 and
bloodpressure33 decline in thedementia prodrome, individu-
als with β-amyloid positivity may have lower vascular scores
(ie, reverse causality).
In addition to the role of apolipoprotein E ε4 in enhanc-
ing β-amyloid deposition,34 it is involved in lipidmetabolism
and enhances atheroma deposition.35 It has been suggested
that thenegative associationofvascular risk factorswithbrain
pathology, includingβ-amyloiddeposition,36brainvolumes,37
and WMHV,38 may be exacerbated in individuals who carry
theAPOE ε4 allele.However,we foundnoevidenceof this. As
anticipated, APOE ε4 carriage was strongly associated with
β-amyloid–positive status, but there was no independent as-
sociationwith other imagingmeasures. This provides further
evidence that the APOE ε4 allele influences late-life demen-
tia risk through its association with β-amyloid deposition,
while vascular risk influences late-life brain health through
nonamyloidogenic pathways. Since many other pathological
pathways are implicated in the development of AD, including
neuroinflammation39 and tau-mediated damage,40 vascular
risk may still directly influence AD risk via other mecha-
nisms,whichwewerenot able to investigate.However, an as-
sociation with hippocampal volume was only seen at age 36
years, and thiswas substantially attenuated afterWBVadjust-
ment, suggesting this association was driven by global brain
changes rather thanaregion-specific change,whichmighthave
been anticipated if vascular risk was directly associated with
AD pathology.
We used a composite vascular score rather than examin-
ing vascular risk factors individually: vascular risk factors of-
ten cluster together, for instance, in the context of the meta-
bolic syndrome (ie, obesity,hypertension, anddiabetes),41 and
therefore consideration of global cardiovascular risk is more
relevant in clinical practice. We recently reported associa-
tions between higher blood pressure in midlife and greater
WMHV and smaller brain volumes at age 69 to 71 years. In-
creasingbloodpressure betweenage 36years and43years (ie,
early adulthood intomidlife)was also associatedwith smaller
brain volumes.42 In this analysis, incorporating information
on other vascular risk factors may have increased the power
to detect associations extending back into early adulthood,
when vascular risk is generally low. Findings from this work
have potential implications for public health strategies, high-
lighting the importanceofvascular riskmodification fromearly
adulthood onwards to maximize benefits to late-life cogni-
tive health. This is particularly pertinent in view of the rising
global obesity epidemic, with associated consequent vascu-
lar effects.
Limitations
Althoughparticipants are broadly representative of thepopu-
lationborn inmainlandBritain in 1946, those in Insight 46 are
exclusively white British individuals, which limits generaliz-
ability to other populations. We have previously demon-
strated that individuals in Insight 46 are healthier than in the
largerNSHD.14 It is therefore likely that, if anything,weareun-
derestimating effect sizes comparedwith the general popula-
tion. We did not have complete data on all individuals and
chose to perform complete-case analysis, assuming data was
missing at random. Reassuringly, results did not meaning-
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fully change on usingmultiple imputation, butwe cannot ex-
cludethepossibility thatadditionalbiaswas introduced ifmiss-
ingness was associated with an imaging outcome. We used a
binary measure of β-amyloid burden and therefore cannot
exclude the possibility that small influences of vascular risk
on β-amyloid deposition are not detected using this ap-
proach. Vascular risk intervention may modify associations,
but it is challenging to account for in longitudinal observa-
tional work and was therefore not investigated. Participants
were predominantly dementia-free at the end of data collec-
tion, and therefore we have not examined associations with
cognition and dementia directly. However, brain volume,43
WMHV,44 and β-amyloid pathology44 are all associated with
subsequent cognitive impairment, and it is reasonable to in-
fer that the findings will have implications for future cogni-
tive decline.
Conclusions
Higher vascular risk is associated with smaller WBV and
higher WMHV at age 69 to 71 years, with the strongest asso-
ciation seen with early adulthood vascular risk. There was
no evidence that higher vascular risk influences cognitive
health via β-amyloid deposition. The importance of elevated
vascular risk in early adulthood should be recognized and
appropriate lifestyle modification or other interventions
considered.
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